Abarca and LucyRx announced that they plan to merge. When the merger is finalized in the third quarter of 2026, they will provide prescription drug services to more than 9 million members and $15 billion in drug spend managed. The companies will operate as wholly owned subsidiaries of Healthcare Revolution Partners. Leadership will remain unchanged, with David Blair and Jason Borschow continuing as CEO of their respective companies. David Blair, CEO of LucyRx, and Jason Borschow, CEO of Abarca, spoke to Managed Healthcare Executive about the company’s merger, and the combined company is well-positioned for the PBM market.
Read the full article: 4 Things to Know About the Abarca/LucyRx Merger //
Source: https://www.managedhealthcareexecutive.com/view/4-things-to-know-about-the-abarca-lucyrx-merger